PMEF
AMPH icon

Point72 Middle East FZE’s Amphastar Pharmaceuticals AMPH Stock Holding History

Point72 Middle East FZE’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,161
Closed -$789K – 1477
2023
Q3 		$789K Buy
+17,161
New +$936K 0.03% 659
2023
Q1 		– Sell
-1,782
Closed -$49.9K – 1606
2022
Q4 		$49.9K Buy
+1,782
New +$51.7K ﹤0.01% 1453

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Point72 Middle East FZE's AMPH Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2023, closing a stake of 17,161 shares — an estimated $789K sold.

Point72 Middle East FZE first reported a position in AMPH in Q4 2022 and held it in 2 quarters. The position peaked at $789K in Q3 2023. 277 funds tracked by Wall St. Rank hold AMPH as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Amphastar Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 17,161 Amphastar Pharmaceuticals shares in Q4 2023, an estimated $789K.
  • Point72 Middle East FZE first reported a position in Amphastar Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Amphastar Pharmaceuticals position peaked at $789K in Q3 2023.
  • 277 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.